Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifid triple viable probiotic is a microbial therapeutic preparation composed of three specific strains of live bacteria: *Bifidobacterium longum*, *Lactobacillus acidophilus*, and *Enterococcus faecalis*. It is widely used in clinical practice to regulate the balance of intestinal microflora and treat gastrointestinal disorders such as diarrhea, constipation, and abdominal distension. The mechanism of action involves the replenishment of beneficial bacteria, which helps to inhibit the growth of pathogenic microorganisms, maintain the integrity of the intestinal mucosal barrier, and modulate local immune responses. In oncology, it is being investigated for its potential to prevent radiation-induced enteritis in patients receiving pelvic radiotherapy for gynecological cancers, such as cervical and endometrial cancer, by mitigating the inflammatory damage to the gut microbiome and improving nutritional status.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bifid triple viable probiotic.